SolasCure’s mission is to support healthcare professionals with wound care products that significantly improve the health and wellbeing of patients with chronic wounds. Their product Aurase Wound Gel contains an enzyme isolated and cloned from medical maggots that aids wound healing and debridement. Clinical trials began in the UK in 2021, taking place in centres across the UK, US and Hungary, the final results and medical approval are due this year (2023).  Solascure were named a UK Life Sciences Innovator 2023 by the UK’s Department for International Trade.

SolasCure is actively engaged in discussions with several of the world’s largest wound care players and anticipate a purchase bid or a strategic partnership offer in the very near future.

To read more about SolasCure, please click here